Edgewise Therapeutics (EWTX) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Organon (OGN) over the past year, gaining 161.4% versus a gain of 30.1%. Over five years, EWTX leads with a +123.1% price change compared with -60.5% for OGN. Edgewise Therapeutics is the larger company by market cap ($4.15 billion vs $3.62 billion), about 1.1 times the size.
Organon pays a dividend yielding 0.58%, while Edgewise Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | OGN |
|---|---|---|
| Share price | $38.21 | $13.80 |
| Market cap | $4.15B | $3.62B |
| 1-day change | -3.44% | +0.04% |
| YTD return | +59.46% | +92.33% |
| 1-year return | +161.36% | +30.09% |
| 5-year return | +123.06% | -60.48% |
| P/E ratio (TTM) | — | 17.69 |
| Forward P/E | — | 3.82 |
| EPS (TTM) | $-1.86 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | — | $6.22B |
| Revenue growth (YoY) | — | -2.92% |
| Net income (latest FY) | $-167.79M | $187.00M |
| Gross margin | — | 53.30% |
| Net margin | — | 3.01% |
| 52-week high | $48.51 | $13.80 |
| 52-week low | $14.25 | $5.69 |
| Distance from 52-week high | -21.23% | -0.04% |
| Analyst consensus | buy | none |
| Avg. price target upside | +37.71% | -18.45% |
| Average volume | 1.35M | 2.64M |
| Shares outstanding | 108.60M | 262.61M |
| Employees | 127 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed OGN by 131.3 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
EWTX vs OGN FAQ
Which is bigger, Edgewise Therapeutics or Organon?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.15B compared with $3.62B for Organon (OGN).
Which stock has performed better over the past year, EWTX or OGN?
EWTX returned +161.36% over the past 12 months, compared with +30.09% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Edgewise Therapeutics or Organon?
Organon pays a dividend yielding 0.58%, while Edgewise Therapeutics does not currently pay a regular dividend.
Are Edgewise Therapeutics and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.